Tear Duct Implant Reduces Pain and Inflammation
By HospiMedica International staff writers Posted on 05 Nov 2014 |
Image: The dexamethasone punctum plug below a 17.9-mm wide US coin (Photo courtesy of Ocular Therapeutix).
A new tear duct implant developed to treat inflammation and pain following cataract surgery could be a reliable alternative to medicated eye drops, according to a new study.
Researchers at Texan Eye (Austin, TX, USA) conducted a study to evaluate the dexamethasone punctum plug, an implant that automatically delivers the correct amount of postoperative medication in patients; after 30 days, the plug softens, liquefies and clears through the tear duct. Punctum plugs designed to deliver sustained-release dexamethasone were tested in 60 participants, who were randomly split into two groups. One group of 30 patients receiving a placebo punctum plug, and the other group received a dexamethasone-medicated punctum plug.
At various points throughout the 30 days following cataract surgery the researchers assessed the number of patients with ocular inflammation—measured by the presence of anterior chamber cells in the treated eye—and pain. The researchers concluded that when compared to a placebo, the dexamethasone punctum plug provides sustained reductions of inflammation and pain for up to one month following cataract surgery. The study was presented at the annual meeting of the American Academy of Ophthalmology (AAO), held during October 2014 in New Orleans (LA, USA).
“Most people who have cataract surgery are older and may have a difficult time adhering to a postoperative eye drop regimen for various reasons,” said lead author ophthalmologist Thomas Walters, MD. “Getting eye drops onto the eye can be difficult for anybody, especially those who might have trouble holding the bottle or targeting the drops onto the eye. The punctum plug eliminates those variables and will make recovering from surgery far easier for cataract patients.”
The dexamethasone punctum plug is under development by Ocular Therapeutix (Bedford, MA, USA), and is entering phase 3 trials. It is inserted noninvasively through the punctum, residing within the canaliculus, delivering a four week tapered release of corticosteroid to the ocular surface. The plug also contains a visualization aid for retention monitoring throughout the treatment period. After therapy is complete, the implant resorbs and exits the nasolacrimal system without need for removal by the physician.
Related Links:
Texan Eye
Ocular Therapeutix
Researchers at Texan Eye (Austin, TX, USA) conducted a study to evaluate the dexamethasone punctum plug, an implant that automatically delivers the correct amount of postoperative medication in patients; after 30 days, the plug softens, liquefies and clears through the tear duct. Punctum plugs designed to deliver sustained-release dexamethasone were tested in 60 participants, who were randomly split into two groups. One group of 30 patients receiving a placebo punctum plug, and the other group received a dexamethasone-medicated punctum plug.
At various points throughout the 30 days following cataract surgery the researchers assessed the number of patients with ocular inflammation—measured by the presence of anterior chamber cells in the treated eye—and pain. The researchers concluded that when compared to a placebo, the dexamethasone punctum plug provides sustained reductions of inflammation and pain for up to one month following cataract surgery. The study was presented at the annual meeting of the American Academy of Ophthalmology (AAO), held during October 2014 in New Orleans (LA, USA).
“Most people who have cataract surgery are older and may have a difficult time adhering to a postoperative eye drop regimen for various reasons,” said lead author ophthalmologist Thomas Walters, MD. “Getting eye drops onto the eye can be difficult for anybody, especially those who might have trouble holding the bottle or targeting the drops onto the eye. The punctum plug eliminates those variables and will make recovering from surgery far easier for cataract patients.”
The dexamethasone punctum plug is under development by Ocular Therapeutix (Bedford, MA, USA), and is entering phase 3 trials. It is inserted noninvasively through the punctum, residing within the canaliculus, delivering a four week tapered release of corticosteroid to the ocular surface. The plug also contains a visualization aid for retention monitoring throughout the treatment period. After therapy is complete, the implant resorbs and exits the nasolacrimal system without need for removal by the physician.
Related Links:
Texan Eye
Ocular Therapeutix
Latest Surgical Techniques News
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons